LLY
Eli Lilly and Company (LLY) Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release
Eli Lilly and Company (LLY) Surges 5.1% — Developing Story
Eli Lilly and Company (LLY) Surges 5.1% — Developing Story
Eli Lilly and Company (LLY) Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release
Eli Lilly and Company (LLY) Patients with Crohn’s disease maintained steroid-free remission for three years with Lilly’s Omvoh (mirikizumab-mrkz)
Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release
Eli Lilly and Company (LLY) Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release
Eli Lilly and Company (LLY) TD Cowen’s 46th Annual Health Care Conference
Eli Lilly and Company (NYSE: LLY) FY 2026 Corporate Conference
Eli Lilly and Company (LLY) Lilly’s Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release
Eli Lilly and Company (LLY) Sec Form 10K
Eli Lilly and Company (NYSE: LLY) Sec Form 10K
Eli Lilly and Company (LLY) Lilly To Acquire Orna Therapeutics To Advance Cell Therapies
Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release